Cytokine network in autoimmune haemolytic anaemia: new probable targets for therapy

Mainwaring, 2000, Fatal cold anti-i autoimmune haemolytic anaemia complicating hairy cell leukaemia, Br. J. Haematol., 109, 641, 10.1046/j.1365-2141.2000.02058.x Pavithran, 1999, Chronic lymphatic leukemia presenting as hemolytic anaemia, Indian J. Med. Sci., 53, 490 Mauro, 2000, Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features, Blood, 95, 2786, 10.1182/blood.V95.9.2786.009k30_2786_2792 Ertem, 2000, Immune thrombocytopenia and hemolytic anemia as a presenting manifestation of Hodgkin disease, Pediatr. Hematol. Oncol., 17, 181, 10.1080/088800100276550 Gloneux, 1998, Autoimmune hemolytic anemia associated with a mature ovarian teratoma, Arch. Pediatr., 5, 41 Lands, 1996, Renal cell carcinoma and autoimmune hemolytic anemia, South Med. J., 89, 444, 10.1097/00007611-199604000-00022 Zuncker, 1985, Anemia in cancer, Cancer Invest., 3, 249, 10.3109/07357908509039786 Rytting, 1996, Hemolytic disorders associated with cancer, Hematol. Oncol. Clin. North Am., 10, 365, 10.1016/S0889-8588(05)70343-9 Calderoni, 1994, Autoimmune processes as paraneoplastic manifestations in familiar breast carcinoma, Dtsch. Med. Wochenschr., 119, 1194, 10.1055/s-2008-1058821 Sokol, 1994, Erythrocyte autoantibodies, autoimmune haemolysis, and carcinoma, J. Clin. Pathol., 47, 340, 10.1136/jcp.47.4.340 Hollstein, 1991, p53 mutation in human cancers, Science, 253, 49, 10.1126/science.1905840 Kuhn, 1999, p53 autoantibodies in patients with autoimmune diseases: a quantitative approach, Autoimmunity, 31, 229, 10.3109/08916939908994068 Drappa, 1996, Fas gene mutation in the Canale–Smith syndrome, an inherited lymphoprolipherative disorder associated with autoimmunity, N. Engl. J. Med., 335, 1643, 10.1056/NEJM199611283352204 Shenoy, 2001, Defective apoptosis in lymphocyte and the role of IL-12 in autoimmunne hematologic cytopenias, Clin. Immunol., 99, 266, 10.1006/clim.2001.5017 Theophilopulous, 1995, The basis of autoimmunity. Part II. Genetic predisposition, Immunol. Today, 16, 150, 10.1016/0167-5699(95)80133-2 Mosmann, 1989, Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol., 7, 145, 10.1146/annurev.iy.07.040189.001045 Romagnani, 1997, The Th1 and Th2 paradigm, Immunol. Today, 18, 263, 10.1016/S0167-5699(97)80019-9 Romagnani, 1994, Lymphokine production by human T cells in disease states, Annu. Rev. Immunol., 12, 227, 10.1146/annurev.iy.12.040194.001303 Viallard, 1999, Th1 and Th2 cytokine production by peripheral blood mononuclear cells from patients with systemic lupus erythematosus, Clin. Exp. Immunol., 115, 189, 10.1046/j.1365-2249.1999.00766.x Horwitz, 1998, Decreased production of IL-12 and other Th1-type cytokine in patients with recent onset systemic lupus erythematosus, Arthritis Rheum., 41, 838, 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S Snapper, 1993, Towards a comprehensive view of immunoglobulin class switching, Immunol. Today, 14, 15, 10.1016/0167-5699(93)90318-F Goldman, 1991, Th2 cells in systemic autoimmunity: insights from allogenic diseases and chemically-induced autoimmunity, Immunol. Today, 12, 223, 10.1016/0167-5699(91)90034-Q Fagiolo, 1999, Enhanced IL-10 production in vitro by monocytes in autoimmune haemolytic anaemia (AIHA), Immunol. Invest., 28, 347, 10.3109/08820139909062268 Llorente, 1993, Spontaneous production of IL-10 by B lymphocytes and monocytes in systemic lupus erythematosus, Eur. Cytokine Netw., 4, 421 Howard, 1992, Biological properties of IL-10, Immunol. Today, 13, 198, 10.1016/0167-5699(92)90153-X Ishida, 1994, Continuous administration of anti-IL-10 antibodies delays onset of autoimmunity in NZB/W F1 mice, J. Exp. Med., 179, 305, 10.1084/jem.179.1.305 Houssiau, 1997, IL-12 inhibits in vitro immunoglobulin production by human lupus PBMC, Clin. Exp. Immunol., 108, 375, 10.1046/j.1365-2249.1997.d01-1009.x Trinchieri, 1997, Biological properties and therapeutic applications of IL-12, Eur. Cytokine Netw., 8, 305 Tokano, 1999, Levels of IL-12 in sera of patients with SLE-relation to Th1- and Th2-derived cytokines, Clin. Exp. Immunol., 116, 169, 10.1046/j.1365-2249.1999.00862.x Fagiolo, 1996, Lymphocyte activation and cytokine production in autoimmune hemolytic anaemia (AIHA), Autoimmunity, 24, 147, 10.3109/08916939608995360 Trembleau, 1995, The role of IL-12 in the induction of organ-specific autoimmune diseases, Immunol. Today, 16, 383, 10.1016/0167-5699(95)80006-9 Segal, 1998, An IL-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease, J. Exp. Med., 187, 537, 10.1084/jem.187.4.537 O’Hara, 1998, Advanced colorectal cancer is associated with impaired IL-12 and enhanced IL-10 production, Clin. Cancer Res., 4, 1943 Mtzer, 2001, Randomized multicenter phase II trial of subcutaneous recombinant human IL-12 versus IFN-α2a for patients with advanced renal cell carcinoma, J. Interferon Cytokine Res., 21, 257, 10.1089/107999001750169934 Tsung, 1997, IL-12 induces Th1-directed antitumor response, J. Immunol., 158, 3359, 10.4049/jimmunol.158.7.3359 Lebeaut, 1997, Clinical development of IL-10, Eur. Cytokine Netw., 8, 303 Keystone, 1998, IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis, Rheum. Dis. Clin. North Am., 24, 629, 10.1016/S0889-857X(05)70030-2 Asadullah, 1998, IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach, J. Clin. Invest., 101, 783, 10.1172/JCI1476 Ramachandra, 1996, Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL, J. Clin. Invest., 98, 1788, 10.1172/JCI118978